PharmaCyte Biotech (PMCB) Stock Price, News & Analysis

Company Overview

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Key Stats

• Today's Range: $1.65 to $1.74
• 50-Day Range: $1.50 to $1.85
• 52-Week Range: $1.39 to $2.58
• Volume: 9,782 shs
• Average Volume: 17,690 shs
• Market Capitalization: $11.64 million
• P/E Ratio: 3.15
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PMCB Stock Analysis - Frequently Asked Questions

How have PMCB shares performed this year?

PharmaCyte Biotech's stock was trading at $1.57 at the beginning of 2025. Since then, PMCB shares have increased by 7.0% and is now trading at $1.68.
View the best growth stocks for 2025 here.

How were PharmaCyte Biotech's earnings last quarter?

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) issued its earnings results on Friday, December, 13th. The company reported ($0.29) earnings per share for the quarter.

How do I buy shares of PharmaCyte Biotech?

Shares of PMCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of PharmaCyte Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PharmaCyte Biotech investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), ASML (ASML), General Electric (GE), Oracle (ORCL) and Nokia Oyj (NOK).

Company Calendar

• Last Earnings: 12/13/2024
• Today: 1/21/2025
• Next Earnings (Estimated): 3/17/2025
• Fiscal Year End: 4/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PMCB
• CUSIP: N/A
• CIK: 1157075
• Web: pharmacyte.com
• Phone: 917-595-2850
• Fax: 917-595-2851
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $0.53
• Trailing P/E Ratio: 3.17
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $330,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: 0.76%
• Return on Assets: 0.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.47
• Quick Ratio: 4.47

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.27 per share
• Price / Book: 0.51

Miscellaneous

• Outstanding Shares: 6,970,000
• Free Float: 6,459,000
• Market Cap: $11.71 million
• Optionable: Optionable
• Beta: -0.22